1. Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease.
- Author
-
Field JJ, Strunk RC, Knight-Perry JE, Blinder MA, Townsend RR, and DeBaun MR
- Subjects
- Acetates pharmacology, Acetates therapeutic use, Adolescent, Adult, Anemia, Sickle Cell complications, Anti-Asthmatic Agents pharmacology, Anti-Asthmatic Agents therapeutic use, Asthma complications, Asthma drug therapy, Biomarkers, Child, Cohort Studies, Cyclopropanes, Female, Fetal Hemoglobin genetics, Hemoglobin C Disease genetics, Hemoglobin C Disease urine, Heterozygote, Hospitalization statistics & numerical data, Humans, Ischemia etiology, Ischemia urine, Leukotriene Antagonists pharmacology, Leukotriene Antagonists therapeutic use, Male, Pain etiology, Quinolines pharmacology, Quinolines therapeutic use, Retrospective Studies, Sickle Cell Trait genetics, Sickle Cell Trait urine, Sulfides, Young Adult, beta-Thalassemia genetics, beta-Thalassemia urine, Anemia, Sickle Cell urine, Leukotriene E4 urine, Pain urine
- Abstract
Baseline level of the cysteinyl leukotriene (CysLT), leukotriene E4 (LTE4), is associated with an increased pain rate in children and adults with sickle cell disease (SCD). To provide additional evidence for a role of CysLTs in the pathogenesis of vaso-occlusion, we tested the hypothesis that LTE4 levels will increase within an individual during painful episodes compared to baseline. In a cohort of 19 children and adults with SCD, median LTE4 levels increased from 82.36 pg/mg creatinine at baseline to 162.81 pg/mg creatinine during a painful episode (P < 0.001). These data further support a contribution of CysLTs to the process of vaso-occlusion., (Copyright 2009 Wiley-Liss, Inc.)
- Published
- 2009
- Full Text
- View/download PDF